美国食品药品监督管理局（FDA）近期批准的用于65岁以下全髋关节置换术患者的陶瓷对陶瓷轴承的中期结果。
Midterm Outcomes of the Recently FDA Approved Ceramic on Ceramic Bearing in Total Hip Arthroplasty Patients Under 65 Years of Age.
作者信息
Aoude Ahmed A, Antoniou John, Epure Laura M, Huk Olga L, Zukor David J, Tanzer Michael
机构信息
Division of Orthopaedic Surgery, McGill University, Montreal Genral Hospital, Montreal, QC, Canada.
SMBD-Jewish General Hospital, Department of Orthopedics, McGill University, Montreal, QC, Canada.
出版信息
J Arthroplasty. 2015 Aug;30(8):1388-92. doi: 10.1016/j.arth.2015.03.028. Epub 2015 Mar 31.
The present study aimed to evaluate the mid-term results of the fourth generation of ceramic on ceramic (CC) bearing. Demographics, surgical technique, complications, clinical and radiologic outcomes were analyzed in a series of 133 consecutive CC total hip arthroplasties (THAs) with a newest generation CC bearings to determine if these provide safe and well performing bearings. At the last follow-up, there were no cases of ceramic fracture or chipping and no revision surgery necessary for bearing related complication. One hip underwent two staged revision for infection and another underwent revision for dislocation, resulting in an overall 98.5% survival rate at a mean of 6 years. The newest generation of CC bearings provides a reliable and safe bearing in young, active patients undergoing THA.
本研究旨在评估第四代陶瓷对陶瓷（CC）轴承的中期结果。对一系列连续133例采用最新一代CC轴承的全髋关节置换术（THA）患者的人口统计学、手术技术、并发症、临床和放射学结果进行分析，以确定这些轴承是否安全且性能良好。在最后一次随访时，未发生陶瓷骨折或碎裂病例，也无需因轴承相关并发症进行翻修手术。1例髋关节因感染接受了两阶段翻修，另1例因脱位接受了翻修，平均6年时的总生存率为98.5%。最新一代CC轴承为接受THA的年轻、活跃患者提供了可靠且安全的轴承。
Zotero 插件